Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- dabigatran
- isavuconazonium
Interactions between your drugs
dabigatran isavuconazonium
Applies to: dabigatran, isavuconazonium
MONITOR: Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of P-glycoprotein (P-gp), such as dabigatran. The proposed mechanism is isavuconazole inhibition of P-gp-mediated efflux of these drugs.
MANAGEMENT: Caution is advised if isavuconazonium sulfate is used concomitantly with drugs that are substrates of P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever isavuconazonium sulfate is added to or withdrawn from therapy with these drugs. Patients receiving concomitant dabigatran should be monitored closely for the development of bleeding complications and the dosage of dabigatran adjusted as necessary.
References (4)
- (2025) "Product Information. Cresemba (isavuconazole)." Pfizer Australia Pty Ltd
- (2025) "Product Information. Cresemba (isavuconazole)." Pfizer Ltd
- (2025) "Product Information. Cresemba (isavuconazonium)." Astellas Pharma US, Inc
- (2024) "Product Information. Cresemba (isavuconazole)." Avir Pharma Inc
Drug and food interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Report options
- Switch to consumer interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Eliquis
Eliquis (apixaban) is used to reduce the risk of stroke and systemic embolism in patients with ...
Xarelto
Xarelto (rivaroxaban) is a factor Xa inhibitor used to reduce the risk of blood clots and stroke in ...
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Lovenox
Lovenox is used to prevent deep vein thrombosis (DVT) which can lead to blood clots in the lungs ...
Coumadin
Coumadin is used to prevent heart attacks, strokes, and blood clots in veins and arteries. Learn ...
Pradaxa
Pradaxa (dabigatran) is used to prevent stroke and blood clots in patients with atrial ...
Ecotrin
Ecotrin is used for angina, angina pectoris prophylaxis, ankylosing spondylitis, antiphospholipid ...
Jantoven
Jantoven is used for antiphospholipid syndrome, chronic central venous catheterization, deep vein ...
Heparin Sodium
Heparin Sodium is used for angina, anticoagulation during pregnancy, antiphospholipid syndrome ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.